Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENSAR, Inc. - Common Stock (NQ:LNSR)

12.56 +0.01 (+0.08%)
Streaming Delayed Price Updated: 9:30 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about LENSAR, Inc. - Common Stock

< Previous 1 2 Next >
Lensar (LNSR) Q2 Revenue Rises 10%
Via The Motley Fool
Topics Artificial Intelligence
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
Alcon Eyes Surgical Edge With LENSAR Buyout: Details
Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract... 
Via Benzinga
LENSAR - Top Healthcare Equipment Stock
LENSAR, Inc., a commercial-stage medical device company. 
Via Talk Markets
Topics Stocks / Equities
Earnings Scheduled For February 27, 2025
 
Via Benzinga
LNSR Stock Earnings: LENSAR Misses EPS, Beats Revenue for Q2 2024
LNSR stock results show that LENSAR missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Earnings Preview: LENSAR
 
Via Benzinga
LENSAR's Earnings Outlook
 
Via Benzinga
Earnings Preview For LENSAR
 
Via Benzinga
LENSAR Earnings Perspective: Return On Capital Employed
 
Via Benzinga
3 Under-$10 Stocks With the Potential to Make You a Millionaire
Buying stocks under $10 might be one of the best ways to breach that million mark. Take a look at these three potential candidates. 
Via InvestorPlace
LNSR Stock Earnings: LENSAR Beats EPS, Beats Revenue for Q1 2024
LNSR stock results show that LENSAR beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Earnings Scheduled For March 4, 2024
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Why NanoVibronix Shares Are Trading Higher By 49%; Here Are 20 Stocks Moving Premarket
Gainers AgileThought, Inc. (NASDAQ: AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday. 
Via Benzinga
A Preview Of LENSAR's Earnings
 
Via Benzinga
LENSAR Earnings Perspective: Return On Capital Employed
 
Via Benzinga
LENSAR: Q2 Earnings Insights
  LENSAR (NASDAQ:LNSR) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 49 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 85 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 41 companies made new 52-week lows. 
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
LENSAR Earnings Perspective: Return On Capital Employed
LENSAR (NASDAQ:LNSR) brought in sales totaling $8.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.27%, resulting in a loss of $6.76 million. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.